Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.67 |
| ▸ | BCL2 | P10415 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | BLM | P54132 | 3/20 | 0.50 |
| ▸ | PTPRC | P08575 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | APAF1 | O14727 | 3/20 | 0.50 |
| ▸ | TDP2 | O95551 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205250 | 0.96 | MCL1 (0.61) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL395884 | 0.96 | MCL1 (0.72) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL19075869 | 0.88 | ALOX15 (0.46) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL7979992 | 0.86 | BCL2 (0.91) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL6230652 | 0.86 | NPC1 (0.61) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL27615612 | 0.82 | MAOA (0.73) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2769983 | 0.81 | BCL2 (1.00) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL6029304 | 0.81 | NPC1 (0.67) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL11072946 | 0.77 | BCL2 (0.67) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL6629644 | 0.77 | BCL2 (0.67) | MCL1BCL2SMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | SENHWA BIOSCIENCES, INC. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | SENHWA BIOSCIENCES, INC. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | SENHWA BIOSCIENCES, INC. (TW) | 2011-03-17 | — | — | US | disclosed |
| CN-1809572-B | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS INC | 2010-05-12 | — | — | CN | disclosed |
| US-7612063-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612063-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612063-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7141565-B1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20060229303-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006078317-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| CN-1809572-A | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS INC (US) | 2006-07-26 | — | — | CN | disclosed |
| US-20060029950-A1 | Substituted quinobenzoxazine analogs and methods of using thereof | CYLENE PHARMACEUTICALS, INC. | 2006-02-09 | — | — | US | disclosed |
| EP-1610759-A2 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | Cylene Pharmaceuticals, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050085468-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS | 2005-04-21 | — | — | US | disclosed |
| WO-2004091504-A2 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085468-A1 | Substituted quinobenzoxazine analogs | CYP3A5, UGT2B7, CYP2D6 | MCL1 1125/4885BCL2 1703/4885SMN1; SMN2 4550/4885 |
| US-20060229303-A1 | Substituted quinobenzoxazine analogs | CYP3A5, UGT2B7, CYP2D6 | MCL1 1125/4885BCL2 1703/4885SMN1; SMN2 4550/4885 |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYP3A5, UGT2B7, CYP2D6 | MCL1 1125/4885BCL2 1703/4885SMN1; SMN2 4550/4885 |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | TP53, CCNY, ACIN1 | MCL1 6/4885BCL2 57/4885SMN1; SMN2 3304/4885 |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | EIF2AK2, DDX21, POLI | MCL1 36/4885BCL2 629/4885SMN1; SMN2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.